MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Analysts Set Maplight Therapeutics, Inc. (NASDAQ:MPLT) Target Price at $31.80
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell?
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
MapLight Therapeutics Announces Pricing of Initial Public Offering
US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On
MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments